<DOC>
	<DOC>NCT02721641</DOC>
	<brief_summary>This study is designed to provide continued access to intravenous (IV) Herceptin and to evaluate long-term outcomes and overall safety in participants with stable disease and human epidermal growth factor 2 (HER2)-overexpressing metastatic or locally advanced cancer who have completed a prior study with IV Herceptin.</brief_summary>
	<brief_title>A Continuation Study of Herceptin (Trastuzumab) in Participants With Metastatic or Locally Advanced Cancer</brief_title>
	<detailed_description />
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Ongoing participants from any completed global Rochesponsored Herceptin trial Participants enrolled in any Rochesponsored Herceptin trial who have at least stable disease (or whose disease has not recurred) during Herceptin therapy at the end of the leadin trial Available study termination data (including tumor assessment and laboratory data) on the Case Report Form for the leadin trial Judged eligible by the investigator following a thorough risk/benefit assessment, if signs of chronic heart failure developed during the leadin trial Pregnant or nursing women Women of childbearing potential unless using effective contraception as determined by the investigator Severe dyspnea at rest requiring supplementary oxygen therapy Severe uncontrolled systemic disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>